secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001739410-24-000040
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio announces J&J collaboration with $0.5M upfront and $6.6M equity for FNAIT
--------------------------------------------------------------------------------

- Collaboration with J&J: Rallybio receives $0.5M upfront, up to $3.7M milestones for FNAIT data sharing and awareness.
- J&J affiliate JJDC invests $6.6M via purchase of 3.6M shares in private placement at ~$1.82/share.
- Rallybio's RLYB212 (preventative for non-alloimmunized) and J&J's nipocalimab (for alloimmunized) target FNAIT; Phase 2 for RLYB212 expected H2 2024.
- JJDC locked up from selling shares for 180 days; collaboration agreement expires April 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/rlyb-20240409.htm
  HTML page:      https://secwatch.observer/filing/0001739410-24-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer